Key information

🔎 Fund Overview

NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company’s key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.